Extension of Tocilizumab Dose Intervals in Patients with Low to Moderate Disease Activity Rheumatoid Arthritis using IL-6 Serum Level as Starting Criteria.
Not Applicable
- Conditions
- rheumatoid arthritis
- Registration Number
- JPRN-UMIN000008404
- Lead Sponsor
- Japan Labour Health and Welfare Organization, Yokohama Rosai Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patient who has no contraindications to methotrexate or to tocilizumab. 2) Patients who are inadequate to enter this trail due to the other reasons by physicians judgments.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The rate of patients completed 48 weeks with tocilizumab 8-weeks dose intervals.
- Secondary Outcome Measures
Name Time Method